Longevity.

Stanford Medicine study reveals we experience tw

Treating Alzheimer’s patients with combination

A recent study published in

When you use links on our website, we may earn a f

Are you curious about the differences between co

Longevity.

In a pioneering move for

Topical treatment is designed to reactivate dorm

At the recently concluded

Longevity.

Recent research highlights a surprising link bet

José Cordeiro and Felix Werth explore how the d

Genetic testing firm closes drug discovery divis

Longevity.

Ellie Aldridge, a rising star in kitefoiling, ha

Researchers develop new method to create complex

Partnership aims to bring C2N’s portfolio of A

A new study published in

A recent study by Stanford researchers has uncov

In recent years, understanding the leading cause

Preclinical study investigates neuron-targeted p

Identifying vision problems in children can be c

The chemical composition of the brain can substa

Unified company aims to ‘industrialize drug di

Colin Farrell has been a passionate advocate for

Bioniq founder on why taking a personalized appr

Companies seek to leverage disease risk detectio

The most recent report from The Lancet Commissio

Longevity.

Obesity presents a major global health challenge

Longevity world mourns a pioneer of aging resear

Company targets Phase 2 trial of oral Alzheimer’s drug that inhibits the activity of microglia to combat neuroinflammation. US biotech NeuroTherapia has secured $12.3 million in the first close of a Series B financing round to progress its mission to tackle central nervous system diseases, with an initial focus on Alzheimer’s. While many companies are targeting the removal of toxic proteins like beta amyloid, tau and alpha synuclein, the Cleveland Clinic spinout is addressing neuroinflammation, a factor increasingly recognized as crucial in the progression of CNS diseases. NeuroTherapia’s focus is on developing orally available small-molecule drugs that inhibit the activity of microglia, immune cells in the CNS that contribute to neuroinflammation. By modulating these cells, the company aims to reduce inflammation without disrupting the clearance of toxic proteins, thereby improving neuronal function and survival. Microglia, the central immune cells in the brain, can exist in two states: the neuroprotective M2 phenotype, which helps clear amyloid β, and the neurotoxic M1 phenotype, which contributes to inflammation and synaptic damage. In Alzheimer’s disease and other neurodegenerative conditions, there is an increased prevalence of the M1 state, exacerbating the disease. NeuroTherapia’s lead candidate, NTRX-07, is designed to activate the cannabinoid type 2 (CB2)…

A recent study published in

A recent study published in

In recent years, a staggering 50% decrease in ni

Longevity.

Have you noticed a sudden puffiness or swelling

New study shows that raising levels of fatty aci

On a mission to promote healthier eating habits,